PT3541784T - Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical - Google Patents

Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical

Info

Publication number
PT3541784T
PT3541784T PT178077798T PT17807779T PT3541784T PT 3541784 T PT3541784 T PT 3541784T PT 178077798 T PT178077798 T PT 178077798T PT 17807779 T PT17807779 T PT 17807779T PT 3541784 T PT3541784 T PT 3541784T
Authority
PT
Portugal
Prior art keywords
modulators
derivatives useful
azetidine derivatives
novel azetidine
cortical
Prior art date
Application number
PT178077798T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of PT3541784T publication Critical patent/PT3541784T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT178077798T 2016-11-18 2017-11-17 Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical PT3541784T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16199545 2016-11-18

Publications (1)

Publication Number Publication Date
PT3541784T true PT3541784T (pt) 2023-11-22

Family

ID=57348567

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178077798T PT3541784T (pt) 2016-11-18 2017-11-17 Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical

Country Status (10)

Country Link
US (1) US10875829B1 (enExample)
EP (1) EP3541784B1 (enExample)
JP (1) JP6990702B2 (enExample)
CN (1) CN109963834B (enExample)
DK (1) DK3541784T5 (enExample)
ES (1) ES2962865T3 (enExample)
FI (1) FI3541784T3 (enExample)
PL (1) PL3541784T3 (enExample)
PT (1) PT3541784T (enExample)
WO (1) WO2018091687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112198237B (zh) * 2020-05-28 2021-08-06 扬子江药业集团广州海瑞药业有限公司 一种盐酸奈康唑杂质检测控制分析方法
WO2025008506A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy
WO2025008504A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
JP5621087B2 (ja) * 2008-11-24 2014-11-05 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な3−フェニル−アゼチジン誘導体
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての3−フェニル−3−メトキシピロリジン誘導体
WO2010084428A1 (en) 2009-01-20 2010-07-29 Pfizer Inc. Substituted pyrazinone amides
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2536689A1 (en) * 2010-02-17 2012-12-26 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SG195085A1 (en) 2011-06-07 2013-12-30 Pfizer Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
SG11201403909RA (en) * 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
RU2017107521A (ru) * 2014-08-27 2018-10-01 Ф. Хоффманн-Ля Рош Аг Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar
WO2016073420A1 (en) * 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
CN107646031B (zh) 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物
CN108026030B (zh) 2015-09-18 2020-10-09 正大天晴药业集团股份有限公司 一种氘代化合物的制备方法
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret

Also Published As

Publication number Publication date
WO2018091687A1 (en) 2018-05-24
JP2019535715A (ja) 2019-12-12
DK3541784T5 (da) 2024-09-16
DK3541784T3 (en) 2023-10-23
EP3541784A1 (en) 2019-09-25
ES2962865T3 (es) 2024-03-21
CN109963834B (zh) 2023-04-14
EP3541784B1 (en) 2023-09-13
JP6990702B2 (ja) 2022-01-13
US10875829B1 (en) 2020-12-29
FI3541784T3 (fi) 2023-10-02
PL3541784T3 (pl) 2024-03-11
CN109963834A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
HUS2500016I1 (hu) Diaril-makrociklusok mint proteinkináz-modulátorok
IL272888A (en) Uses of piperidinyl-indole derivatives
ZA201802150B (en) Compounds useful as modulators of trpm8
EP3408268B8 (en) Benzimidazole derivatives as modulators of ror-gamma
EP3230956A4 (en) Augmentation of stop-motion content
IL304618A (en) Modulators of pcsk9 expression
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
IL267993A (en) Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
PT3223827T (pt) Composição de fibras alimentares
SMT202100551T1 (it) Derivati di sobetirome
EP3180347A4 (en) Synthesis of cephalosporin compounds
IL273237A (en) Novel heterocyclic compounds as MGLUR7 modulators
DK3541784T3 (en) Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP3344280A4 (en) BONE FORMATION
ZA201707936B (en) Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
GB201409783D0 (en) Phthalimide derivatives as modulators of WNT pathway
HK40001214A (en) Benzimidazole derivatives as modulators of ror-gamma
AU2015904123A0 (en) Augmentation of connective tissue
AU2015903565A0 (en) Formation of bone
AU2014903769A0 (en) Brachial effects of infarcts